Shang Hai Zheng Quan Bao·2026-02-02 18:49Core Viewpoint - Chengdu Enwei Investment (Group) Co., Ltd. and its acting-in-concert parties have reduced their shareholding in Enwei Pharmaceutical Co., Ltd. from 69.10% to 65.22% through a non-public transfer of 4,000,000 shares at a price of 26.54 yuan per share, totaling 106,160,000 yuan, without affecting the company's control structure or governance [3][4][9]. Group 1 - The equity change involves Chengdu Enwei Investment (Group) Co., Ltd. and its acting-in-concert parties, which collectively held over 5% of Enwei Pharmaceutical's shares. The shareholding ratio decreased from 69.10% to 65.22% after the transfer [3][9]. - The transfer method was a non-public inquiry transfer, and it did not trigger a mandatory tender offer. The shares acquired through this transfer cannot be transferred for six months [3][4][15]. - The total number of shares transferred was 4,000,000, representing 3.89% of the company's total share capital, with a transaction price of 26.54 yuan per share [4][12]. Group 2 - The inquiry transfer was organized by CITIC Securities, which confirmed that the process adhered to relevant regulations and was conducted fairly and transparently [14][32]. - A total of 451 institutional investors received the subscription invitation, and 32 valid subscription bids were received during the designated time [22][24]. - The final allocation resulted in 11 institutional investors receiving shares, confirming the transfer price and quantity as per the established rules [25][26].